Serologicals Corporation Agrees to Acquire LINCO; Solidifies Serologicals as a Leader in Multiplexing Marketplace

Serologicals Corporation (NASDAQ: SERO) announced today
a definitive agreement to acquire LINCO, a privately owned life
sciences company focused on supplying research assays and test kits
for the Luminex-based Multiplexing platform and other immunoassays.
Based in St. Louis, Missouri, LINCO consists of two companies - LINCO
Research Inc. (LRI) and LINCO Diagnostic Services, Inc. (LDS). LRI is
a life sciences provider of Multiplex, ELISA and RIA immunoassay
products and technologies, while LDS provides bioanalytical contract
services supporting research and new pharmaceutical drug development.
   The combination of these companies strengthens Serologicals'
Luminex-based Multiplexing portfolio, which is part of our Research
business segment. With Upstate's focus on cell signaling and LINCO's
strengths in the detection of secreted proteins, including a
leadership position in endocrinology and metabolic diseases,
Serologicals will offer the largest portfolio of Luminex-based
Multiplexing products and services to better serve customer needs.
Further, the acquisition enables Serologicals to address the metabolic
disease research market, a rapidly growing segment, given its
relevance to the aging baby boomer population.
   "We are excited about today's announcement that brings the LINCO
companies, capabilities and resources into our company," said David A.
Dodd, President and CEO of Serologicals. "We anticipate that this
acquisition will strengthen the Research segment's financial profile
as LINCO offers strong double-digit revenue growth and greater than
60% gross margins. Given Upstate and LINCO's complementary product
portfolios, Serologicals will be well positioned to better meet
customers' needs. With dedicated new product development and
commercial operations efforts, we believe the combination of these two
companies will result in an enviable position in the Luminex-based
Multiplexing market."
   "LINCO, as a part of Serologicals, offers a unique merger
opportunity," remarked Ronald Gingerich, Founder, Chairman and Chief
Executive Officer of LINCO. "In addition to the complementary fit of
our products, we believe our core capability in kit development
combined with Serologicals best practices in new product development
will result in an impressive company offering superior, high quality
products to our customers. This productivity will be matched with
Serologicals' dedicated sales force, ultimately resulting in greater
penetration into the life science marketplace and better service to
our customers."
   LINCO forecasts over $22.0 million in 2006 full year revenues.
Under the terms of the agreement, Serologicals will pay $64.5 million
in cash for the business plus an additional $10.3 million for the land
and buildings currently occupied by the unit. Serologicals expects the
acquisition will be consummated in April 2006, pending expiration of
the waiting period under the Hart-Scott-Rodino Antitrust Improvements
Act and other customary closing conditions. The acquisition of LINCO
is expected to be accretive for Serologicals in fiscal year 2006 with
a $0.03 to $0.04 positive impact on pro forma earnings per share for
the nine month period.
   Privately owned, LINCO is headquartered in St. Louis, Missouri.
With 109 employees, LINCO has established a strong position in the
Luminex based Multiplexing market primarily due to its high quality
reputation of offering immunoassay reagents, kits and services in the
endocrinology and metabolic diseases field.
   Serologicals will host a conference call on Friday, March 24, 2006
at 9:00 a.m. (Eastern Time) to discuss this transaction. To
participate in the call, dial (800) 573- 4752 (domestic) or (617)
224-4324 (international), confirmation code: 37319244. The call will
be web cast through Serologicals' website at www.serologicals.com or
www.StreetEvents.com. If you are unable to participate in the call or
do not have access to the internet, a 15-day playback will start at
11:00 a.m. (Eastern Time) on Friday, March 24, 2006. To listen to the
playback, please call [phone] (domestic) or [phone]
(international), confirmation code: 95497656
   Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta,
GA., is a global leader in developing and commercializing consumable
biological products, enabling technologies and services in support of
biological research, drug discovery, and the bioprocessing of
life-enhancing products. Our customers include researchers at major
life science companies and leading research institutions involved in
key disciplines, such as neurology, oncology, hematology, immunology,
cardiology, proteomics, infectious diseases, cell signaling and stem
cell research. In addition, Serologicals is the world's leading
provider of monoclonal antibodies for the blood typing industry.
   Serologicals employs a total of approximately 1,000 people
worldwide in three Serologicals' companies: Chemicon International,
headquartered in Temecula, California, Upstate Group, LLC,
headquartered in Charlottesville, Virginia and Celliance Corporation,
headquartered in Atlanta, Georgia.
   For more information, please visit our website:
www.serologicals.com.
   This release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Words or phrases such as "should result," "are expected to," "we
anticipate," "we estimate," "we project" or similar expressions are
intended to identify forward-looking statements. These statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those expressed in any
forward-looking statements. These risks and uncertainties include,
without limitation, our expectations regarding accretion and our
expectations regarding LINCO's fiscal year 2006 revenue. You should
not place undue reliance on forward-looking statements, since the
statements speak only as of the date that they are made, and
Serologicals undertakes no obligation to update these statements based
on events that may occur after the date of this press release